Advances in the treatment of RET-fusion-positive lung cancer. (June 2021)

• Record Type: Journal Article
• Authors: Pall, Georg; Gautschi, Oliver
• Is Part Of: Lung cancer. Volume 156(2021)
• Page Start: 136
• Page End: 139
• Publication Date: 2021-06
• Subjects: NSCLC -- RET-fusion -- RET-inhibitors; Lungs -- Cancer -- Periodicals; Lung Neoplasms -- Abstracts; Lung Neoplasms -- Periodicals; Poumons -- Cancer -- Périodiques; Lungs -- Cancer; Periodicals; Electronic journals; Electronic journals; 616.99424
• DOI: 10.1016/j.lungcan.2021.04.017
• Languages: English
• ISSNs: 0169-5002

Abstract

Highlights: RET-fusions define a clinically relevant subgroup of NSCLC-patients. Selective RET-inhibitors show high efficacy and favourable toxicity. Acquired resistance can be considered the most prominent challenge in the future. Abstract: Ten years ago, RET-fusions were discovered as oncogenic drivers and potential drug targets in approximately 1% of metastatic lung adenocarcinomas. Several multikinase inhibitors were tested in clinical trials, however, their antitumor activity was limited. Recently, two selective and potent RET-inhibitors were approved for the treatment of patients with metastatic RET-fusion-positive lung cancer (RET-NSCLC). Here, we discuss the two RET-inhibitors selpercatinib and pralsetinib, and the management of patients with RET-fusion positive NSCLC.